organon news - Search News

Organon, Roivant

Organon makes $1.2bn play for Roivant’s immuno-dermatology subsidiary

As part of the acquisition, Organon will acquire psoriasis treatment Vtama, which could soon be approved in atopic dermatitis.

Seeking Alpha · 3d

Roivant's Sale Of Dermavant To Organon: A Strategic Win-Win In Atopic Dermatitis

Organon acquires ROIV's Dermavant for $1.2B, expanding their dermatology portfolio and potentially increasing sales. Click here to read my most recent analysis.

NJBIZ · 4d

Organon to acquire Dermavant in $1.2B deal

The Roivant company is dedicated to developing and commercializing innovative therapeutics in immune-dermatology.

Reuters · 5d

Organon to buy Roivant's dermatology unit for up to $1.2 billion

However, Organon was down 1.4%. Dermavant's Vtama cream, approved by the U.S. Food and Drug Administration in May 2022, treats psoriasis, a common long-term inflammatory skin disease. The FDA is also reviewing an application to expand the use of the drug ...

MarketWatch · 5d

Organon to Buy Roivant's Dermavant Unit in Deal Worth Up to $1.2 Billion

Organon has agreed to buy medical dermatology company Dermavant Sciences, a majority-owned unit of Roivant Sciences, in a deal worth up to $1.2 billion. Organon on Wednesday said it will make an up-front payment of $175 million,

Organon: A Surprising Deal

Organon shares have stabilized in recent times, with gradual debt reduction and structural growth allowing for a valuation re ...

FiercePharma5d

Organon pays up to $1.2B to acquire Dermavant and its steroid-free skin cream Vtama

With its latest acquisition, women’s health outfit Organon is bringing its dermatology business to the U.S. with a ...

5don MSN

Roivant Flips a Skin Drug to Organon

Selling plaque psoriasis drug Vtama to Organon looks like another win for Roivant, which has been buying overlooked drugs, ...

pharmaphorum4d

Organon makes dermatology play with $1.2bn Dermavant buyout

Organon is paying $175 million upfront to buy Roivant's dermatology unit Dermavant and its topical psoriasis therapy Vtama, ...

Assessing Organon’s Strategic Acquisition of Dermavant: A Balanced Hold Recommendation Amid Growth and Challenges

Analyst Terence Flynn of Morgan Stanley maintained a Hold rating on Organon (OGN – Research Report), retaining the price target of ...

CSR Wire6d

Organon Issues 2023 ESG Report, Highlighting Strides in Women’s Health Equity and Environmental Stewardship

Organon (NYSE: OGN), a global healthcare company with a focus on women’s health, today released its 2023 Environmental, ...

Barron's16h

Organon & Co.

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International stock ...

Organon to Acquire Dermavant including its Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%

VTAMA cream is a novel, non-steroidal topical therapy approved for treatment of plaque psoriasis in adults and is under FDA review for an ...

Court revives more than 500 lawsuits over Fosamax femur fracture risk

A U.S. appeals court on Friday revived more than 500 lawsuits alleging that Merck & Co failed to warn that its osteoporosis ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results

Related topics